Repros Therapeutics names president, CEO
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
Repros Therapeutics Inc. appointed Larry Dillaha as the company's permanent president and CEO.
Dillaha, who previously held chief medical officer roles at Insys Therapeutics Inc. and Sciele Pharma Inc., will also fill a vacancy on the company's board.
Dillaha was performing the duties on an interim basis following the resignation of Joseph Podolski.
